Clinical trials: Malignant Melanoma
Advanced Melanoma and Normal or Impaired, Advanced Melanoma
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821…
- Trial name
- Asher-BioAB821 (NCT07027488)
- Testing
- AB821
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
Nivolumab (OpdivoTM, BMS), a human IgG-4 anti-PD-1 monoclonal antibody has demonstrated anti-tumor activity in patients with advanced melanoma.
- Trial name
- ipniv (NCT02941744)
- Testing
- nivolumab, ipilimumab
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Melanoma, Dysplastic Nevus Syndrome
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions.
- Trial name
- NCT00040352
- Where
- 2 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Skin Cancer
Integrated Basic Science Within the Instructional Design of Pattern Recognition Training
Investigators hypothesize that the introduction of basic science explanations within the instructional design of case-based training in visual diagnostics will improve students' learning curves, retention, and retrieval of…
- Trial name
- AISC-ISF (NCT05087485)
- Testing
- education
- Where
- Denmark
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Melanoma
LATe TreatmENT Related Toxicity in Melanoma (LATENT)
Recent improvements in advanced melanoma treatment with immunotherapy have dramatically improved patient survival. Longer survival however has come at a cost of toxicity.
- Trial name
- LATENT (NCT06414343)
- Testing
- Observational - no intervention
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust